• Wondering whether HealthEquity at a last close of US$88.11 is offering good value, or if the stock price already reflects most of what you can reasonably expect.
• The stock has risen 7.2% over the past week and 6.9% over the past month, yet is still down 3.3% year to date and has declined 11.0% over the past year, while showing a 59.9% gain over three years and a 6.0% gain over five years.
• Recent coverage has focused on how HealthEquity fits into the broader healthcare and benefits administration space, including commentary on its role in health savings account administration and related services. This context helps frame why the market might be reassessing both the stock's risk profile and its long term potential.
• HealthEquity currently has a valuation score of 4/6, based on how it screens across six separate checks for potential undervaluation. The next sections will walk through the main valuation methods used, and will also point to a more comprehensive way to think about value that appears at the end of this article.

Approach 1: HealthEquity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock might be worth by projecting future cash flows and then discounting them back to today using a required rate of return.

For HealthEquity, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about US$232.6 million. Based on analyst inputs and extrapolated estimates from Simply Wall St, projected free cash flow reaches about US$704.3 million in 2035, with intermediate years such as 2026 and 2029 at US$413.0 million and US$529.0 million respectively.

Rolling all of these cash flows into the DCF framework gives an estimated intrinsic value of US$167.18 per share. Compared with the recent share price of US$88.11, this model suggests the stock trades at about a 47.3% discount. This indicates potential undervaluation on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests HealthEquity is undervalued by 47.3%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: HealthEquity Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it links what you pay for the stock to the earnings the business is already generating. A higher or lower P/E often reflects what the market is expecting for future growth and how much risk investors see in those earnings.

HealthEquity currently trades on a P/E of 34.6x. This sits above the Healthcare industry average of about 24.6x, yet below the peer group average of about 70.8x. On their own, these comparisons do not tell you what the stock should trade at, only how it lines up against broad reference points.

Simply Wall St’s Fair Ratio for HealthEquity is 25.4x. This is a proprietary estimate of what a “normal” P/E could look like given the company’s earnings growth profile, profit margins, industry, market cap and risk characteristics. Because it adjusts for these factors, the Fair Ratio can be more informative than a simple comparison with peers or the sector. With the current P/E of 34.6x sitting above the Fair Ratio, this framework suggests the stock may be pricing in richer expectations than those inputs would imply.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your HealthEquity Narrative

Earlier it was mentioned that there is an even better way to think about valuation. Meet Narratives, a simple tool on Simply Wall St’s Community page that lets you attach a clear story about HealthEquity to your numbers by linking your view of its future revenue, earnings and margins to a forecast, then to a fair value you can compare directly with the current share price.

Instead of only looking at a single DCF or P/E figure, you choose or build a Narrative that reflects your perspective. As new information such as earnings reports, regulatory updates or news on HSA adoption is added, the forecasts and fair value in that Narrative refresh automatically so you can quickly see whether the gap between price and fair value has widened or closed.

For HealthEquity, for example, one investor on Simply Wall St might align with the more bullish view that supports a fair value around US$128.00 based on expectations for margins of about 21.0% and a future P/E of roughly 31.7x, while another might lean toward the cautious end closer to US$86.00. Narratives allow you to see exactly which assumptions sit behind each of those views and decide which story fits your own thinking.

Do you think there's more to the story for HealthEquity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.